|
GB0012528D0
(en)
*
|
2000-05-23 |
2000-07-12 |
Univ Palackeho |
Triterpenoid derivatives
|
|
GB0219052D0
(en)
*
|
2002-08-15 |
2002-09-25 |
Cyclacel Ltd |
New puring derivatives
|
|
GB0226583D0
(en)
*
|
2002-11-14 |
2002-12-18 |
Cyclacel Ltd |
Compounds
|
|
GB0229581D0
(en)
*
|
2002-12-19 |
2003-01-22 |
Cyclacel Ltd |
Use
|
|
CN1897950A
(zh)
|
2003-10-14 |
2007-01-17 |
惠氏公司 |
稠合芳基和杂芳基衍生物及其使用方法
|
|
MX2007004051A
(es)
|
2004-10-07 |
2007-05-24 |
Boehringer Ingelheim Int |
Pi3-quinasas.
|
|
DE602005023333D1
(de)
|
2004-10-15 |
2010-10-14 |
Takeda Pharmaceutical |
Kinaseinhibitoren
|
|
EP1928437A2
(en)
|
2005-08-26 |
2008-06-11 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
EP2258359A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation with sabcomelin
|
|
DE102005048072A1
(de)
*
|
2005-09-24 |
2007-04-05 |
Bayer Cropscience Ag |
Thiazole als Fungizide
|
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
CA2625153A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
|
AU2006308889A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
GABA receptor mediated modulation of neurogenesis
|
|
DE102006001161A1
(de)
*
|
2006-01-06 |
2007-07-12 |
Qiagen Gmbh |
Verfahren zum Nachweis von Cytosin-Methylierungen
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
US20070238746A1
(en)
*
|
2006-04-06 |
2007-10-11 |
Trixi Brandl |
Thiazolyl-dihydro-chinazoline
|
|
US7517995B2
(en)
|
2006-04-06 |
2009-04-14 |
Boehringer Ingelheim International Gmbh |
Thiazolyl-dihydro-cyclopentapyrazole
|
|
US7691868B2
(en)
*
|
2006-04-06 |
2010-04-06 |
Boehringer Ingelheim International Gmbh |
Thiazolyl-dihydro-quinazoline
|
|
AU2007238690B2
(en)
*
|
2006-04-12 |
2013-05-02 |
Vertex Pharmaceuticals Incorporated |
4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase PLK1 inhibitors for the treatment of proliferative disorders
|
|
EP2382975A3
(en)
|
2006-05-09 |
2012-02-29 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
US8779154B2
(en)
|
2006-09-26 |
2014-07-15 |
Qinglin Che |
Fused ring compounds for inflammation and immune-related uses
|
|
EA200970361A1
(ru)
|
2006-10-09 |
2010-02-26 |
Такеда Фармасьютикал Компани Лимитед |
Ингибиторы киназы
|
|
WO2009047359A1
(en)
|
2007-10-12 |
2009-04-16 |
Ingenium Pharmaceuticals Gmbh |
Inhibitors of protein kinases
|
|
EP2100894A1
(en)
|
2008-03-12 |
2009-09-16 |
4Sc Ag |
Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
|
|
JP5530422B2
(ja)
*
|
2008-04-07 |
2014-06-25 |
アムジエン・インコーポレーテツド |
細胞周期阻害薬としてのｇｅｍ−二置換およびスピロ環式アミノピリジン／ピリミジン
|
|
EP2350084B1
(en)
|
2008-10-17 |
2015-06-24 |
Boehringer Ingelheim International GmbH |
Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor
|
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
UY32748A
(es)
|
2009-07-02 |
2011-01-31 |
Novartis Ag |
2-carboxamida-cicloamino-ureas
|
|
SG183192A1
(en)
|
2010-03-10 |
2012-09-27 |
Ingenium Pharmaceuticals Gmbh |
Inhibitors of protein kinases
|
|
US9498471B2
(en)
|
2011-10-20 |
2016-11-22 |
The Regents Of The University Of California |
Use of CDK9 inhibitors to reduce cartilage degradation
|
|
AU2015333689A1
(en)
|
2014-10-14 |
2017-05-25 |
The Regents Of The University Of California |
Use of CDK9 and BRD4 inhibitors to inhibit inflammation
|
|
US20170283445A1
(en)
|
2016-04-05 |
2017-10-05 |
University Of South Carolina |
Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins
|
|
CN109803972B
(zh)
*
|
2017-04-01 |
2021-11-23 |
晟科药业（江苏）有限公司 |
1h-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
|
|
CN111094291B
(zh)
*
|
2017-08-11 |
2022-06-21 |
晟科药业（江苏）有限公司 |
1h-吡唑并[4,3-h]喹唑啉类化合物作为蛋白激酶抑制剂
|
|
US11162083B2
(en)
|
2018-06-14 |
2021-11-02 |
University Of South Carolina |
Peptide based inhibitors of Raf kinase protein dimerization and kinase activity
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
|
US11472791B2
(en)
|
2019-03-05 |
2022-10-18 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
|
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
WO2021023104A1
(zh)
*
|
2019-08-02 |
2021-02-11 |
成都赛诺希亚生物科技有限公司 |
1h-[1，2，3]三唑并[4，5-h]喹唑啉类化合物作为蛋白激酶抑制剂
|
|
CR20220066A
(es)
|
2019-08-14 |
2022-11-28 |
Incyte Corp |
Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
|
|
WO2021072232A1
(en)
|
2019-10-11 |
2021-04-15 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
|
WO2022111634A1
(zh)
*
|
2020-11-26 |
2022-06-02 |
成都赛璟生物医药科技有限公司 |
杂芳基并喹唑啉类化合物作为蛋白激酶抑制剂
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
